Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning
Open Access
- 29 January 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (2), 252-262
- https://doi.org/10.1038/sj.bjp.0707582
Abstract
Ischaemia-reperfusion (I/R) is a pivotal mechanism of organ injury during stroke, myocardial infarction, organ transplantation and vascular surgeries. Ischaemic preconditioning (IPC) is a potent endogenous form of tissue protection against I/R injury. On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms. However, there is evidence suggesting that endocannabinoids are overproduced during various forms of I/R, such as myocardial infarction or whole body I/R associated with circulatory shock, and may contribute to the cardiovascular depressive state associated with these pathologies. Previous studies using synthetic CB1 receptor agonists or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models. In contrast, several follow-up reports have shown protection afforded by CB1 receptor antagonists, but not agonists. Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage. This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.Keywords
This publication has 127 references indexed in Scilit:
- GPR55 and the vascular receptors for cannabinoidsBritish Journal of Pharmacology, 2007
- The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effectsBritish Journal of Pharmacology, 2007
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJournal of the American College of Cardiology, 2007
- Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsBritish Journal of Pharmacology, 2007
- Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injuryThe FASEB Journal, 2007
- Cannabinoid CB2Receptor Activation Decreases Cerebral Infarction in a Mouse Focal Ischemia/Reperfusion ModelJournal of Cerebral Blood Flow & Metabolism, 2007
- Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptorsBritish Journal of Pharmacology, 2006
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- A biosynthetic pathway for anandamideProceedings of the National Academy of Sciences of the United States of America, 2006
- The Pathophysiology and Treatment of SepsisThe New England Journal of Medicine, 2003